Initiator Pharma Investor Relations Material

Initiator Pharma A/S is a Danish clinical-stage biopharmaceutical company focusing on developing treatments for unmet medical needs related to the central and peripheral nervous systems. The company’s portfolio primarily targets disorders such as erectile dysfunction (ED) and neuropathic pain. Its clinical programs include drug candidates for both psychogenic and organic ED as well as a rare disease program for Trigeminal Neuralgia, a chronic pain condition. Initiator Pharma leverages its expertise in monoamine reuptake inhibitors, which increase key neurotransmitters like dopamine to treat various neurological conditions. The company is headquartered in Copenhagen, Denmark, and its shares are listed on the Nasdaq Stockholm.